Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal Treatment for Treatment-resistant Schizophrenia
NCT02926976Unknown
- Sponsor
- Shanghai Mental Health Center
- Start
- Nov 2016
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of risperidone, aripiprazole and valproic acid in schizophrenia (6 arms), sponsored by Shanghai Mental Health Center. Primary endpoint: Positive and Negative Syndrome Scale at 12 weeks. Status: unknown.
02
Drugs
risperidonearipiprazolevalproic acid
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02926976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02926976.